In vivo cytogenetic activity of sulphonylurea drugs in man.
A cytogenetic investigation of diabetic patients undergoing treatment with sulphonylurea drugs, particularly chlorpropamide, shows that significantly more chromatid aberrations and chromosome exchange aberrations are present in the lymphocytes of these patients compared with controls. This is taken as evidence of possible mutagenic activity by these drugs, although the possibility cannot be ruled out that the diabetic state itself is a contributory factor.
D000328:Adult; D002747:Chlorpropamide / Q000009:adverse effects; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D003920:Diabetes Mellitus / Q000188:drug therapy; D005260:Female; D005905:Glyburide / Q000009:adverse effects; D006801:Humans; D008214:Lymphocytes / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D013453:Sulfonylurea Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D014042:Tolazamide / Q000009:adverse effects; D014178:Translocation, Genetic
D013453:Sulfonylurea Compounds; D014042:Tolazamide; D005905:Glyburide; D002747:Chlorpropamide